Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169190 | 0.96 | MAPT (0.55) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL2160433 | 0.94 | FAAH (0.63) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL3000228 | 0.94 | MAPT (0.53) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL2170746 | 0.93 | FAAH (0.54) | MAPTFAAHMEN1KMT2A | |
| SCHEMBL2999877 | 0.92 | MAPT (0.61) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL2168258 | 0.91 | FAAH (0.65) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL3004659 | 0.91 | PTGS2 (0.53) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL4386918 | 0.91 | PTGS2 (0.53) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL3001888 | 0.90 | MAPT (0.46) | MAPTFAAHHTTSMN1; SMN2PTGER3 | |
| SCHEMBL2160424 | 0.90 | TDP1 (0.52) | MAPTFAAHSMN1; SMN2PTGER3RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | MAPT 997/4885FAAH 109/4885HTT 632/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAPT 2737/4885FAAH 1/4885HTT 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.